Skip to content

Fospropofol for Sedation During Elective Awake Intubation

Status
Withdrawn
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01289483
Enrollment
0
Registered
2011-02-03
Start date
2011-02-28
Completion date
2011-04-30
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Impaired Airway Clearance

Keywords

awake fiberoptic intubation (AFI), difficult airway, fospropofol

Brief summary

Patients scheduled for awake fiberoptic intubation (AFI) because of potential difficult airway will be consented prior to intubation ASA Physical Status classification and history of difficult intubation will be recorded at screening. The investigators will also record the results of airway examination including Mallampati classification, thyromental distance, mouth opening, neck circumference, neck range of motion, presence or absence of beard and overbite, history of neck radiation, and mandibular protrusion test Informed consent will be obtained prior to the procedure from those patients who meet the inclusion and exclusion criteria. Standard hemodynamic monitoring will be used in all patients including EKG, blood pressure, heart rate, respiratory rate and oxygen saturation. Modified Observer's Assessment of Alertness/Sedation (MOAA/S) scale will be used to assess the level of alertness/sedation. Two consecutive MOAA/S scores of 4 will be considered as the desired effect of moderate sedation. For AFI procedure, IV will be started and oxygen will be administered. 4 L of oxygen will be delivered through nasal canula until the completion of the AFI procedure. Patient head will be positioned in the sniffing position, Topical anesthesia would be achieved using the topical administration of 4 percent lidocaine using atomized and MaDgic nebulizer, and 2% xylocaine Jel applied to the surface of Williams airway in a total dose of lidocaine not exceeding 10 mg/kg. Patients will be randomized to one of the four fospropofol treatment arms: 2, 3.5, 5, or 6.5 mg/kg

Interventions

After the initial bolus dose of study drug is given, a maximum of two supplemental doses of fospropofol at 25% of the initial dose will be permitted. Fospropofol supplements will be administered every 4 min

Sponsors

Eisai Inc.
CollaboratorINDUSTRY
The Cleveland Clinic
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 64 Years
Healthy volunteers
No

Inclusion criteria

* Age: between 18-64 years of age * ASA physical status 1-3 ( Except patients with severe cardiac and/or pulmonary disease * Weight 60-90 Kg * Elective surgery requiring awake FOI * Male or female, female patients should not be pregnant (documented by morning of surgery urine pregnancy test result as per routine hospital policy) or lactating

Exclusion criteria

* Previous exposure to any experimental drug within 30 days prior to study drug administration * Raised intracranial pressure * Patients for whom propofol is contraindicated * Allergy to midazolam and/or fentanyl

Design outcomes

Primary

MeasureTime frameDescription
Rescue intubation neededevery 4 minutes during procedure, day 1Requiring rescue midazolam and or fentanyl to facilitate intubation
Hypotensionevery 2 minutes, during procedure, day 1Development of hypotension ( defined as blood pressure drop of more than \>30 % of base line) and/or hypoxemia ( SaO2 \< 90% or a drop of \>5% of baseline , whichever is lower)

Secondary

MeasureTime frameDescription
ease of intubationseconds, after intubation, day 1anesthesiologists' assessment of ease of intubation on a visual analog scale (VAS) of 0-10, with 0 being very easy, and 10 being very difficult.
Patient recall and satisfactionend of procedure,day 1Patient recall and satisfaction
hypertensionevery 2 minutes, during procedure day 1Development of hypertension ( increase in blood pressure of \> 30% of baseline), and/or tachycardia (120 beat/min or increase in heart rate of \> 30% of base line, whichever is higher )
Failed intubationseconds, day 1Failed intubation
unresponsivenessseconds, during procedure, day 1Patient becoming un-responsive and /or requiring bag-mask Ventilation
Time to intubateseconds, during procedure, day 1Time to intubation ( first fospropofol bolus to positive EtCO2 )
Total dose of midazolam and fentanyl usedend of procedure, day 1Total dose of midazolam and fentanyl used

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026